Continuing Pharmacy Education / CE Master List / Time to Learn about New Cardiac Drugs-RECORDED WEBINAR
Please use this button to register in our system as a new user, or to purchase a CE Activity.
For free CE's, returning users can simply click the "TAKE TEST/EVALUATION" button on the right.
Please use this button when you have completed the CE Activity and are ready to take the quiz and complete the evaluation.

Time to Learn about New Cardiac Drugs-RECORDED WEBINAR

About this Course

This course is a recorded (home study version) of the CE Finale Encore Webinars.

 

Learning Objectives

Upon completion of this application based CE Activity, a pharmacist will be able to:

  • Select the appropriate first and adjunctive therapies for LDL lowering in patients with differing risks according to guideline recommendations
  • Compare and contrast the mechanism of action and potential utility of the new LDL lowering drugs bempedoic acid and inclisirin versus traditional options
  • Describe hypertrophic cardiomyopathy and its risks
  • Identify the mechanism of action and potential utility of mavacamten versus agents currently recommended in guidelines

Release and Expiration Dates

Released:  December 16, 2022
Expires:  December 16, 2025

Course Fee

$17 Pharmacist

ACPE UAN

0009-0000-22-056-H01-P

Session Code

22RW56-TXJ88

Accreditation Hours

1.0 hours of CE

Additional Information

 

How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-22-056-H01-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

C. Michael White, PharmD, FCCP, FCP
BOT Distinguished Professor and Chair of Pharmacy Practice
University of Connecticut School of Pharmacy
Storrs, CT              

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

  • Dr. White has no relationships with ineligible companies

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Content

Post Test

Mary Maple is an 80-year old with angina pectoris, what intensity of statin therapy should she receive and how much should her LDL be reduced?
a) Moderate intensity, 30%
b) High intensity, 50%
c) Low intensity, 20%

Mary Maple is an 55-year old with angina pectoris, what intensity of statin therapy should she receive and how much should her LDL be reduced?
a) Moderate intensity, 30%
b) High intensity, 50%
c) Low intensity, 20%

According to the CTT relationship, whether the intensity of statin was increased or adjunctive therapy with ezetimibe or evolocumab was used, the relationship between LDL lowering and cardiovascular event reduction had the same relationship
a) True
b) False

Does the CTT relationship apply to inclisirin and bempedoic acid or just to statins, ezetimibe, and PCSK9 inhibitors?
a) Yes
b) Unknown
c) No

Which of the following describes the mechanism of action correctly?
a) Inclisiran inhibits the formation of PCSK9 by inserting small interfering RNA into the cell
b) Bempedoic acid blocks the binding of PCSK9 to the LDL receptor
c) Both of the mechanisms are described correctly

Which of the new cholesterol reducing drugs can cause tendon rupture and increased uric acid?
a. Inclisiran
b. Bempedoic acid
c. Both agents

Which of the following agents can be given every six months once steady state concentrations are achieved?
a. Inclisiran
b. Bempedoic acid
c. Both agents

Hypertrophic cardiomyopathy can lead to what adverse events?
a. Atrial and ventricular arrhythmias
b. Stroke
c. Both of these issues

Mavacamten might be able to replace which of the following HCM treatments?
a. Beta-blockers of Non-DHP CCBs
b. ICDs or anticoagulants
c. Disopyramide or septal reduction therapies

Mavacamten should not be used if the left ventricular ejection fraction goes below what value?
a. 20%
b. 30%
c. 40%
d. 50%

Handouts

Download

VIDEO